An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals.

Trial Profile

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Planned end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top